SPRB SPRUCE BIOSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1683553 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-90.2%
TTM net income YoY-21.4%
TTM EPS YoY-55.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-7,100.0%
Net margin-6,869.3%
FCF margin-6,821.8%
EBITDA margin-7,096.4%
Returns
ROE-167.9%
ROA-119.1%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets64.8%
Debt / equity0.10x
Current ratio1.54x
Interest coverage-353.48x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.8%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $0 | $697,000 |
| R&D expense | $18.13M | $12.16M | $7.58M | $4.10M | $5.01M | -$430,000 | $10.84M | $21.46M |
| SG&A expense | $5.85M | $4.35M | $4.41M | $7.00M | $3.22M | $3.12M | $3.65M | $3.31M |
| Operating income | -$23.98M | -$16.51M | -$11.99M | -$11.10M | -$8.23M | -$2.69M | -$14.49M | -$24.07M |
| Interest expense | $1.20M | $1.10M | $674,000 | $6,000 | $19,000 | $29,000 | $36,000 | $56,000 |
| Net income | -$24.01M | -$16.23M | -$12.27M | -$14.65M | -$8.21M | -$2.07M | -$14.04M | -$23.56M |
| EBITDA | -$23.24M | -$15.88M | -$11.73M | -$11.10M | -$8.23M | -$2.69M | -$14.49M | -$24.07M |
| EPS (basic) | -8.51 | -6.68 | -8.94 | — | -14.58 | -3.50 | -23.95 | — |
| EPS (diluted) | -8.51 | -6.68 | -8.94 | — | -14.58 | -3.50 | -23.95 | — |
| Weighted avg. shares (diluted) | 2.82M | 2.43M | 1.37M | — | 563,066 | 591,137 | 586,142 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $87.69M | $96.30M | $54.08M | $48.91M | $10.67M | $16.39M | $25.61M | $38.79M |
| Current assets | $90.30M | $101.15M | $55.03M | $52.11M | $14.52M | $20.95M | $30.58M | $44.21M |
| Total assets | $91.95M | $102.85M | $56.17M | $53.02M | $15.31M | $21.82M | $31.65M | $45.21M |
| Current liabilities | $18.71M | $10.96M | $11.78M | $10.09M | $9.43M | $8.06M | $15.67M | $15.25M |
| Short-term debt | $4.00M | $2.50M | $1.00M | $0 | $539,000 | $943,000 | $1.34M | $1.62M |
| Long-term debt | $3.82M | $4.59M | $5.46M | $0 | $0 | $0 | $0 | $124,000 |
| Total debt | $7.82M | $7.09M | $6.46M | $0 | $539,000 | $943,000 | $1.34M | $1.75M |
| Total liabilities | $25.65M | $19.12M | $21.52M | $10.51M | $9.93M | $8.64M | $16.32M | $16.39M |
| Shareholders' equity | $66.30M | $83.73M | $34.65M | $42.52M | $5.39M | $13.18M | $15.32M | $28.82M |
| Net debt | -$79.87M | -$89.20M | -$47.62M | -$48.91M | -$10.13M | -$15.44M | -$24.27M | -$37.04M |
| Shares outstanding | 2.87M | 2.75M | 1.37M | 1.37M | 563,491 | 563,042 | 42.23M | 563,042 |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.76M | -$22.12M | -$8.73M | -$6.46M | -$5.32M | -$8.83M | -$12.73M | -$20.68M |
| Capital expenditure | $0 | $135,000 | $10,000 | — | $0 | $0 | $0 | $0 |
| Free cash flow | -$13.76M | -$22.25M | -$8.74M | — | -$5.32M | -$8.83M | -$12.73M | -$20.68M |
| Investing cash flow | $0 | -$135,000 | -$10,000 | — | $0 | $0 | $0 | $0 |
| Financing cash flow | $5.16M | $64.47M | $13.92M | $44.69M | -$402,000 | -$400,000 | -$411,000 | -$625,000 |
| Depreciation & amortization | $738,000 | $631,000 | $252,000 | $5,000 | $3,000 | $7,000 | $6,000 | $9,000 |
| Stock-based compensation | $1.10M | $871,000 | $689,000 | $1.69M | $415,000 | -$77,000 | $544,000 | $961,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.